ArticleCureus2025
Secondary Loss of Response to Dopamine Receptor Agonists in the Treatment of Macroprolactinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary loss of response, sometimes termed "acquired resistance," refers to the phenomenon where a patient, initially responsive to DRA therapy, as evidenced by normalized prolactin levels and/or tumor reduction, experiences a recurrence of hyperprolactinemia and/or tumor regrowth despite continued therapy at previously effective doses. This differs from primary resistance, in which patients never respond to treatment. We present an uncommonly described finding of a loss of response of macroprolactinoma treatment to cabergoline after an initial response in this case report. A literature review regarding primary and secondary resistance of prolactinomas to dopamine receptor agonist (DRA) therapy has been conducted. Patient education regarding the rare occurrence of secondary resistance of prolactinomas to DRA therapy can be better guided by this case report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.